---
title: "Akebia Therapeutics: Still Bullish On Vafseo As Auryxia's Revenues Decline"
date: "2025-02-10 13:43:35"
summary: "airdone/iStock via Getty Images Akebia Therapeutics (NASDAQ:AKBA) is currently working on kidney-related diseases, mostly by using its HIF platform. As it stands now, AKBA is transitioning from relying on Auryxia to Vafseo, which is probably the biggest risk it faces today. Nevertheless, Vafseo is seeing some early successes so"
categories:
  - "seekalpha_articles"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha_articles"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1751003304/image_1751003304.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

![ERC enfermedad renal crónica, texto palabras tipografía escrito con letra de madera, salud y medicina](https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1751003304/image_1751003304.jpg?io=getty-c-w750) 



airdone/iStock via Getty Images



Akebia Therapeutics (NASDAQ:[AKBA](https://seekingalpha.com/symbol/AKBA "Akebia Therapeutics, Inc.")) is currently working on kidney-related diseases, mostly by using its HIF platform. As it stands now, AKBA is transitioning from relying on Auryxia to Vafseo, which is probably the biggest risk it faces today. Nevertheless, Vafseo is seeing some early successes so

[seekalpha_articles](https://seekingalpha.com/article/4756570-akebia-therapeutics-still-bullish-on-vafseo-as-auryxia-revenues-decline)
